OncLive® On Air
By OncLive® On Air
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by OncLive® On Air
Category: Health & Fitness
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 4
Reviews: 0
Episodes: 500
Description
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
| Episode | Date |
|---|---|
|
S17 Ep22: Answering Key Clinical Questions About Esophageal Cancer Care: With Peter Enzinger, MD
|
May 13, 2026 |
|
S17 Ep23: FDA Approval Insights: Brexu-Cel for Relapsed/Refractory MCL: With Luhua (Michael) Wang, MD
|
May 13, 2026 |
|
S17 Ep21: Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bond
|
May 12, 2026 |
|
S17 Ep20: Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhD
|
May 08, 2026 |
|
S17 Ep19: Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer
|
May 06, 2026 |
|
S17 Ep18: Metastatic Bladder Cancer 2026 UPDATE
|
May 04, 2026 |
|
S17 Ep16: Show Me the Data®: From Mutation to Action—KRAS as a Therapeutic Target in PDAC
|
May 01, 2026 |
|
S17 Ep15: FES-PET/CT Reshapes Treatment Planning in Lobular Breast Cancer and Beyond: With Megan Kruse, MD
|
May 01, 2026 |
|
S17 Ep14: Treatment Advances in Relapsed SCLC Introduce New Options and Clinical Workflows: With Alissa Cooper, MD
|
Apr 30, 2026 |
|
S17 Ep13: Cases and Conversations: Translating ctDNA Into Clinical Decisions in Breast Cancer
|
Apr 30, 2026 |
|
S17 Ep12: ADCs Change Treatment Paradigms and Challenge Standard AE Management Protocols in TNBC: With Sara Nunnery, MD, MSCI; and Irene Morae Kang, MD
|
Apr 30, 2026 |
|
S17 Ep11: Medical Crossfire® — From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas
|
Apr 29, 2026 |
|
S17 Ep10: Evolving Research Puts a Focus on GLP-1 Agonist Use in Breast Cancer: With Sara Nunnery, MD, MSCI; and Neil M. Iyengar, MD
|
Apr 28, 2026 |
|
S17 Ep9: Medical Crossfire®: Optimizing ESR1 Mutation Detection and Next-Generation Endocrine Therapy Integration in HR+/HER2– Breast Cancer
|
Apr 28, 2026 |
|
S17 Ep17: Localized Bladder Cancer 2026 UPDATE
|
Apr 27, 2026 |
|
S17 Ep8: From Molecular Insights to Clinical Impact: Translating the Latest Advances in Menin Inhibitors Into Practice
|
Apr 27, 2026 |
|
S17 Ep7: RAS/MAP Kinase Pathway Targeting Makes Strides in Gynecologic Cancer Management: With Ursula A. Matulonis, MD; and Elizabeth H. Stover, MD, PhD
|
Apr 24, 2026 |
|
S17 Ep6: Medical Crossfire®: Advancing Personalized Care in TNBC—Integrating Biomarkers, Clinical Evidence, and Emerging Therapies
|
Apr 24, 2026 |
|
S17 Ep5: Medical Crossfire® Expanding Options, Evolving Challenges in Advanced HR+/HER2– Breast Cancer: How Experts Apply the Latest Data
|
Apr 23, 2026 |
|
S17 Ep4: Show Me the Data: Translating Clinical and Practice-Based Evidence on Oral SERDs Into Everyday Care for HR+/HER2– Metastatic Breast Cancer
|
Apr 21, 2026 |
|
S17 Ep3: OncoBytes Adaptive Learning Pathways: Personalizing Treatment Plans to Optimize Adjuvant Therapy in Early-Stage HR+/HER2– Breast Cancer
|
Apr 20, 2026 |
|
S17 Ep2: Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck - Post-CRT Decisions in the Locally Advanced Setting
|
Apr 17, 2026 |
|
S17 Ep1: Medical Crossfire®: PD-L1 Inhibition in Advanced Cutaneous Squamous Cell Carcinoma — Mechanistic Rationale and Clinical Application
|
Apr 15, 2026 |
|
S16 Ep50: Medical Crossfire®: Translating Risk Into Action—Redefining Adjuvant Strategies for Early HR+/HER2– Breast Cancer
|
Apr 14, 2026 |
|
S16 Ep49: Medical Crossfire®: Redefining Frontline and Maintenance Strategies in HER2+ Metastatic Breast Cancer
|
Apr 10, 2026 |
|
S16 Ep48: Shifting the Paradigm in Small Cell Lung Cancer: Targeting Tumor Biology to Transform Patient Outcomes
|
Apr 09, 2026 |
|
S16 Ep47: The Intricacies of Approved Therapies Pose Questions for CLL Management: With Mazyar Shadman, MD, MPH
|
Apr 07, 2026 |
|
S16 Ep46: Coffee Talk: Charting New Pathways With HER2 and TROP2 Therapies – From Early to Advanced Breast Cancer
|
Apr 07, 2026 |
|
S16 Ep45: Facilitating Precision Pathways: Surgical Considerations in Breast Cancer for Tackling Barriers to Genetic Testing and Targeted Therapies
|
Apr 03, 2026 |
|
S16 Ep44: Lifestyle Interventions, Exercise Programs, and Metabolic Medications Are Key to Holistic Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Neil M. Iyengar, MD
|
Apr 02, 2026 |
|
S16 Ep43: FDA Approval Insights: Rucaparib for BRCA Mutation–Associated mCRPC: With David Morris, MD, FACS; and Alan H. Bryce, MD
|
Mar 31, 2026 |
|
S16 Ep41: The Price of Survival: Addressing Financial Toxicity in Gynecologic Oncology With Ursula A. Matulonis, MD; and Katharine M. Esselen, MD, MBA
|
Mar 31, 2026 |
|
S16 Ep37: Show Me the Data®: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD
|
Mar 31, 2026 |
|
S16 Ep42: Variability and Innovation in Small Cell Lung Cancer Care: With Ticiana Leal, MD
|
Mar 31, 2026 |
|
S16 Ep40: FDA Approval Insights: Zongertinib for HER2 TKD–Mutated NSCLC: With Julia Rotow, MD; and Martin Dietrich, MD, PhD
|
Mar 30, 2026 |
|
S16 Ep39: Community Practice Perspectives: Overcoming Barriers in Small Cell Lung Cancer Care: With Misty D. Shields, MD, PhD
|
Mar 30, 2026 |
|
S16 Ep38: Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC
|
Mar 27, 2026 |
|
S16 Ep36: New Trials and Targeted Approaches Advance the Precision of GI Cancer Care: With John Marshall, MD; and Christopher Lieu, MD
|
Mar 27, 2026 |
|
S16 Ep35: T-DXd Trials Transform Treatment for HER2-Positive Breast Cancer: With Sara Nunnery, MD, MSCI; and Kelly E. McCann, MD, PhD
|
Mar 26, 2026 |
|
S16 Ep34: Utilizing Real-World Analyses Help Make Sense of Multiple Approved CAR T-Cell Therapies for ALL: With Jae Park, MD
|
Mar 25, 2026 |
|
S16 Ep33: Real-World Data Support ctDNA-Guided Treatment Strategies in FGFR2-Altered Cholangiocarcinoma: With Marina Baretti, MD
|
Mar 25, 2026 |
|
S16 Ep32: ASCO GU 2026 Takeaways
|
Mar 23, 2026 |
|
S16 Ep31: ctDNA Testing At Progression May Help Detect Resistance and Guide Sequencing in GIST: With Drs Jonathan Trent, MD, PhD, and Neeta Somaiah, MD
|
Mar 20, 2026 |
|
S16 Ep30: ASH Guidelines Provide Key Recommendations for AYA Acute Lymphoblastic Leukemia Management: With Wendy Stock, MD
|
Mar 20, 2026 |
|
S16 Ep29: Novel Treatment Combinations for B-ALL May Help Patients Safely Achieve Remission: With Colin Vale, MD
|
Mar 18, 2026 |
|
S16 Ep28: Medical Crossfire®: Menin Inhibitors in AML—Dissecting the Data to Define the Role
|
Mar 17, 2026 |
|
S16 Ep26: Trans-Arterial Micro-Perfusion Could Boost Systemic Chemotherapy Efficacy in Unresectable Pancreatic Cancer: With Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; and Eric Pletcher, MD
|
Mar 13, 2026 |
|
S16 Ep27: Show Me the Data™—Closing Clinical Gaps in Gastric and Esophageal Cancer: Advancing Targeted Treatment Strategies Across the Care Continuum
|
Mar 13, 2026 |
|
S16 Ep25: Exploring CAR T in Solid Tumors, Clinical Trials, and Cancer Incidence Questions
|
Mar 11, 2026 |
|
S16 Ep24: Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care
|
Mar 11, 2026 |
|
S16 Ep23: Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities
|
Mar 10, 2026 |
|
S16 Ep22: Leading Breast Oncologists Share Advice and Optimism for Future Women in Oncology: With Kelly E. McCann, MD, PhD, and Sara Nunnery, MD, MSCI
|
Mar 08, 2026 |
|
S16 Ep21: FDA Approval Insights: SC Daratumumab Plus VRd Provides Additional Treatment Avenue in Transplant-Ineligible, Newly Diagnosed Myeloma: With Saad Z. Usmani, MD, MBA, FACP, FASCO
|
Mar 06, 2026 |
|
S16 Ep20: Medical Crossfire®: Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment
|
Mar 06, 2026 |
|
S16 Ep20: Incorporating TROP2-Targeted ADCs Into Lung Cancer Treatment Algorithms: With Eric K. Singhi, MD
|
Mar 05, 2026 |
|
S16 Ep19: Show Me the Data™: Incorporating the Latest Advances in Immunotherapy and EGFR-Targeted Treatments for Resectable Early-Stage NSCLC
|
Mar 03, 2026 |
|
S16 Ep18: Integrating Novel Targets and Translational Insights Into SCLC Practice: With Anne Chiang, MD, PhD
|
Feb 27, 2026 |
|
S16 Ep17: Breast Imaging Advances Emphasize the Importance of Patient-Focused Nuclear Medicine Collaboration: With Megan Kruse, MD; and Sophia O’Brien, MD
|
Feb 27, 2026 |
|
S16 Ep16: Cases and Conversations™: Navigating the New Immunotherapy Era in Squamous Cell Anal Carcinoma
|
Feb 27, 2026 |
|
S16 Ep15: Six-Year CheckMate 9LA Data Reinforce Durable Survival in Metastatic NSCLC: With David Carbone, MD, PhD
|
Feb 26, 2026 |
|
S16 Ep14: Pumitamig Represents Potential Immunotherapy Strategy for TNBC: With Sarah Sammons, MD
|
Feb 26, 2026 |
|
S16 Ep13: Positive Phase 3 Data Drive Varegacestat Development in Desmoid Tumors: With Rashmi Chugh MD
|
Feb 26, 2026 |
|
S16 Ep11: Expert Illustrations & Commentaries: Translating the Science of Bispecific Antibodies in Solid Tumors – From Mechanisms to Emerging Data
|
Feb 26, 2026 |
|
S16 Ep12: Evolving Standards and Emerging ADCs Redefine Cervical Cancer Care: With Ursula A. Matulonis, MD; and Susana M. Campos, MD, MPH
|
Feb 25, 2026 |
|
S16 Ep11: Treatment Evolutions Affect First-Line Chemotherapy Selection in Metastatic Pancreatic Cancer: With Rachna T. Shroff, MD, MS, FASCO; and Kristen Spencer, DO
|
Feb 25, 2026 |
|
S16 Ep10: Optimizing TKI Sequencing and Ponatinib Dosing Strategies in CML: With Quinto Gesiotto, MD
|
Feb 25, 2026 |
|
S16 Ep9: A Thoracic Oncologist’s Journey from Iran to Innovation: With Girindra Raval, MD; and Hossein Borghaei, DO, MS
|
Feb 25, 2026 |
|
S16 Ep8: ASCO GU 2026 Preview
|
Feb 24, 2026 |
|
S16 Ep7: Answering Common Questions About Chondrosarcoma Diagnosis and Management: With Hari Desphande, MD, and Philippos Costa, MD
|
Feb 19, 2026 |
|
S16 Ep6: FDA Approval Insights: Subcutaneous Amivantamab for EGFR-Mutated NSCLC: With Alexander I. Spira, MD, PhD, FACP, FASCO
|
Feb 19, 2026 |
|
S16 Ep5: Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care
|
Feb 18, 2026 |
|
S16 Ep4: Comprehensive Ph+ ALL Paradigm Knowledge Informs Frontline Ponatinib Use: With Nicholas Short, MD
|
Feb 13, 2026 |
|
S16 Ep3: Third-Line Treatment Selection in mCRC Is Shaped By Recalibration of Patient Priorities and Molecular Retesting: With Christopher Lieu, MD
|
Feb 11, 2026 |
|
S16 Ep2: “D” is for Diagnosis: Decoding a Difficult Thoracic Malignancy—Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments
|
Feb 11, 2026 |
|
S16 Ep1: Targeted Therapies Take Center Stage for Estrogen Receptor–Positive Breast Cancer: With Aditya Bardia, MD, MPH, FASCO
|
Feb 10, 2026 |
|
S15 Ep50: Bladder Cancer Experts Note Implications of Upfront Enfortumab Vedotin Dose Reduction in Advanced Urothelial Carcinoma: With Ramy Sedhom, MD; Ryan Chow, MD; and Ronac Mamtani, MD, MSCE
|
Feb 05, 2026 |
|
S15 Ep49: Innovation, Equity, and the Future of Oncology: World Cancer Day Spotlight With Deb Schrag, MD, MPH
|
Feb 04, 2026 |
|
S15 Ep48: Multidisciplinary Teams Optimize Surgical and Therapeutic Roles in Advanced CSCC Care: With Eric Whitman, MD; and Vishal Patel, MD, FAAD, FACMS
|
Jan 31, 2026 |
|
S15 Ep47: ASCENT-07 Trial Propels Further Questions About the Role of Earlier-Line ADCs in HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP
|
Jan 31, 2026 |
|
S15 Ep46: Expanded BTK Inhibitor Research Directs the Evolution of Pirtobrutinib Use in CLL: With Andrew Lipsky, MD
|
Jan 31, 2026 |
|
S15 Ep45: Early, Reflex Biomarker Testing Is Critical to Optimizing NSCLC Treatment Decisions Across Disease Stages: With Adam Fox, MD, and Cynthia A. Schandl, MD, PhD
|
Jan 30, 2026 |
|
S15 Ep44: Subcutaneous Isatuximab via On-Body Injector Has Noninferior Efficacy vs IV Delivery in Myeloma: With Sikander Ailawadhi, MD; and Beth Faiman, CNP, PhD
|
Jan 30, 2026 |
|
S15 Ep43: Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP Inhibition in Triple-Negative Breast Cancer
|
Jan 30, 2026 |
|
S15 Ep42: Long-Term Epcoritamab Data Show Durable Responses and Confirmed Safety in LBCL: With Tycel Phillips, MD
|
Jan 30, 2026 |
|
S15 Ep41: Multidisciplinary Breast Cancer Experts Outline Proactive Strategies for Managing Treatment-Related Toxicities: With Neil Iyengar, MD; Heather Moore, CPP, PharmD; and Sarah Donahue, MPH, NP
|
Jan 30, 2026 |
|
S15 Ep40: ELEGANT Trial Seeks to Expand Treatment Options for ER+, HER2-Negative Early Breast Cancer: With Aditya Bardia, MD, MPH, FASCO
|
Jan 29, 2026 |
|
S15 Ep39: Novel Targeted Agents Are Poised to Influence MPN Treatment Paradigm: With John O. Mascarenhas, MD
|
Jan 29, 2026 |
|
S15 Ep38: Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate
|
Jan 29, 2026 |
|
S15 Ep37: Immuno-Oncology and Novel Cell Therapies Set Transformation in Motion for Gynecologic Oncology: With Ursula A. Matulonis, MD; and Rebecca Porter, MD, PhD
|
Jan 28, 2026 |
|
S15 Ep36: Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics
|
Jan 26, 2026 |
|
S15 Ep35: Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2– Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?
|
Jan 22, 2026 |
|
S15 Ep34: Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights
|
Jan 21, 2026 |
|
S15 Ep33: Hot Seat: Converging Lines in the Management of RAS-Altered Cancers
|
Jan 21, 2026 |
|
S15 Ep32: Lisaftoclax Plus Azacitidine May Make New Inroads in Higher-Risk MDS Management: With Guillermo Garcia-Manero, MD
|
Jan 20, 2026 |
|
S15 Ep31: Medical Crossfire® From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium
|
Jan 20, 2026 |
|
S15 Ep30: Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms
|
Jan 20, 2026 |
|
S15 Ep29: Precision in Practice: Advancing Prostate Cancer Care With PSMA-Directed Radioligand Therapy
|
Jan 20, 2026 |
|
S15 Ep28: Emerging CELMoDs Set New Standards for Efficacy and Tolerability in Myeloma: With Rahul Banerjee, MD, FACP
|
Jan 16, 2026 |
|
S15 Ep27: Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life
|
Jan 16, 2026 |
|
S15 Ep26: FDA Approval Insights: Epcoritamab Plus Rituximab/Lenalidomide for Relapsed/Refractory Follicular Lymphoma: With Lorenzo Falchi, MD
|
Jan 15, 2026 |
|
S15 Ep25: FDA Approval Insights: BVd for Relapsed/Refractory Multiple Myeloma: With Surbhi Sidana, MD
|
Jan 09, 2026 |
|
S15 Ep24: PRRT With 177Lu-Edotreotide Improves Outcomes vs Everolimus in Metastatic GEP-NETs: With Jonathan R. Strosberg, MD
|
Jan 07, 2026 |
|
S15 Ep23: Experts Explore Intersections Between Breast Surgery and Radiation for Comprehensive Care: With Hirsch Matani, MD; Elizabeth Zhang-Velten, MD; and Valentina Bonev, MD, DABS, FACS, FSSO
|
Jan 05, 2026 |
|
S15 Ep22: CLL Treatment Paradigm Shifts With Evolving Treatment Sequencing and BTK Inhibition: With Joanna M. Rhodes, MD, MSCE; and Krish Patel, MD
|
Dec 31, 2025 |
|
S15 Ep21: FDA Approval of Enfortumab Vedotin/Pembrolizumab Redefines Perioperative Care for Cisplatin-Ineligible MIBC: With Christof Vulsteke, MD, PhD
|
Dec 31, 2025 |
|
S15 Ep20: Osimertinib Carves a Continuing Role in Perioperative NSCLC Management: With Julia Rotow, MD; and Gavitt Woodard, MD
|
Dec 29, 2025 |
|
S15 Ep19: MRI Techniques Evolve for Glioma Diagnosis, Response Assessment, and Surveillance: With Kathryn S. Nevel, MD; and Michael Veronesi, MD, PhD
|
Dec 25, 2025 |
|
S15 Ep18: ctDNA Testing Opens Avenues for the Future of Breast Oncology: With Jason Mouabbi, MD
|
Dec 22, 2025 |
|
S15 Ep17: Microbiome Profiling Highlights Impact of Butyrate Loss on Post-Transplant Outcomes in Multiple Myeloma: With Pooja M. Phull, MD
|
Dec 18, 2025 |
|
S15 Ep16: Ongoing Sigvotatug Vedotin Exploration Highlights Potential for Biomarker Advancement in NSCLC: With Edward S. Kim, MD, MBA; and Jyoti Malhotra, MD, MPH
|
Dec 17, 2025 |
|
S15 Ep15: ASH 2025 LBA BRUIN-CLL 313 Update: Pirtobrutinib vs Bendamustine/Rituximab in 1L CLL
|
Dec 17, 2025 |
|
S15 Ep14: Optimized Immunotherapy Use and Novel Therapeutic Targets Move the Needle for Endometrial Cancer Management: With Ursula A. Matulonis, MD; and Panagiotis (Panos) A. Konstantinopoulos, MD, PhD
|
Dec 11, 2025 |
|
S15 Ep13: Hepatic Artery Infusion Refines Liver-Directed Care for GI Cancers: With Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; Benjamin Jon Golas, MD, FACS; and Eric Pletcher, MD
|
Dec 09, 2025 |
|
S15 Ep12: VISION Data Show Promise of Tepotinib in Treatment-Naive NSCLC Harboring MET Exon 14 Skipping Mutations: With Catherine Shu, MD
|
Dec 05, 2025 |
|
S15 Ep11: PIPAC Reshapes Peritoneal Cancer Surgery Workflows and Outcomes: With Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; Benjamin Jon Golas, MD, FACS; and Eric Pletcher, MD
|
Dec 03, 2025 |
|
S15 Ep10: ctDNA Assays Are Poised to Reshape Lymphoma Treatment Strategies: With Sarah Rutherford, MD
|
Dec 03, 2025 |
|
S15 Ep9: Personalized Treatment Considerations Guide First-Line Chemo Use in Pancreatic Cancer: With Shubham Pant, MD, MBBS
|
Dec 02, 2025 |
|
S15 Ep8: Accurate Symptom Identification and Guidelines Support LEMS Screening and Diagnosis: With Jacob Sands, MD; and Shailee Shah, MD
|
Dec 01, 2025 |
|
S15 Ep7: Cevostamab-Based Regimens Usher In the Next Wave of Bispecific Antibody Strategies in R/R Myeloma: With Joshua Richter, MD
|
Nov 28, 2025 |
|
S15 Ep6: Tovorafenib Yields Long-Term Efficacy in Pediatric Low-Grade Glioma: With Cassie Kline, MD, MAS
|
Nov 27, 2025 |
|
S15 Ep5: Advances in ADT Personalization and Molecular Imaging Shape Updated NCCN Prostate Cancer Recommendations: With Daniel Spratt, MD
|
Nov 25, 2025 |
|
S15 Ep4: Advances in Breast Cancer ADCs and Endocrine Therapy Take Center Stage at CFS: With Benjamin P. Levy, MD; Kamel Abou Hussein, MD; and Victoria Rizk, MD
|
Nov 24, 2025 |
|
S15 Ep3: Teclistamab-Based Induction Is Effective and Generates MRD Negativity in Newly Diagnosed Myeloma: With Marc S. Raab, MD
|
Nov 24, 2025 |
|
S15 Ep2: FDA Approval Insights: Ziftomenib in NPM1+ R/R AML: With Harry P. Erba, MD, PhD
|
Nov 21, 2025 |
|
S15 Ep1: Insights and Implications of AI’s Expanding Role in Hematologic Malignancy Care: With Justin Taylor, MD
|
Nov 19, 2025 |
|
S14 Ep50: Distinct Risk Factors for Bladder Cancer in Women Necessitate Diligent Early Detection Strategies: With Martha K. Terris, MD, FACS
|
Nov 18, 2025 |
|
S14 Ep49: Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc
|
Nov 14, 2025 |
|
S14 Ep48: PSMA Theranostics, ctDNA Testing, and Combination Regimens in GU Oncology Spark Conversation at CFS: With Benjamin P. Levy, MD; Scott T. Tagawa, MD, MS, FACP, FASCO
|
Nov 13, 2025 |
|
S14 Ep47: Gynecologic Oncology Surgery Advances Are Propelled by Minimally Invasive Techniques: With Ursula Matulonis,
|
Nov 13, 2025 |
|
S14 Ep46: Unique Challenges Characterize Treatment Outcomes for Women With Bladder Cancer: With Martha K. Terris, MD, FACS
|
Nov 11, 2025 |
|
S14 Ep45: Urothelial ESMO 2025 Updates
|
Nov 11, 2025 |
|
S14 Ep44: Research Innovations Spark Promise for Broadening the HR+ Breast Cancer Armamentarium Post-CDK4/6 Inhibition: With Kevin Kalinsky, MD, MS, FASCO
|
Nov 07, 2025 |
|
S14 Ep43: ARROS-1 Data Show Zidesamtinib's Favorable Safety Profile, Spark Discussion to Clarify Its Role in ROS1+ NSCLC: With Stephen Liu, MD
|
Nov 06, 2025 |
|
S14 Ep42: Dynamic Frailty Assessment Underscores Need for Ongoing Evaluation in Transplant-Ineligible Multiple Myeloma: With Hira Mian, MD, MSc, FRCPC
|
Nov 06, 2025 |
|
S14 Ep41: Patient-Reported Outcomes Show Benefits of Isatuximab On-Body Injector in Myeloma: With Sikander Ailawadhi, MD, and Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO
|
Nov 05, 2025 |
|
S14 Ep40: Bladder Cancer Symptom Awareness and Testing Are Crucial for Early Detection in Women: With Martha K. Terris, MD, FACS
|
Nov 04, 2025 |
|
S14 Ep39: Oncology Experts Dive Into Top Data From ESMO 2025
|
Nov 04, 2025 |
|
S14 Ep38: Ongoing ADT Use and Research Emphasizes the Importance of Shared Decision-Making in Prostate Cancer Care: With Neal Shore, MD, FACS
|
Oct 31, 2025 |
|
S14 Ep37: Early Detection, Surgical Innovation, and Multidisciplinary Collaboration Evolve Lung Cancer Care: With Ziad Hanhan, MD, Thomas Bauer, MD, and Rachel NeMoyer, MD
|
Oct 30, 2025 |
|
S14 Ep36: Evolving Research Paradigms, Real-World Data, and Multidisciplinary Collaboration Enhance Bladder Cancer Management: With Amit Mehta, MD
|
Oct 29, 2025 |
|
S14 Ep35: FDA Approval Insights: Y-90 Resin Microspheres for Unresectable HCC: With Armeen Mahvash, MD
|
Oct 27, 2025 |
|
S14 Ep34: FDA Approval Insights: Adjuvant Cemiplimab for High-Risk CSCC: With Vishal A. Patel, MD, FAAD, FACMS
|
Oct 23, 2025 |
|
S14 Ep33: Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum
|
Oct 23, 2025 |
|
S14 Ep32: Evolving Treatment Strategies and Novel Therapies Reshape Secondary AML Management: With Eunice Wang, MD
|
Oct 22, 2025 |
|
S14 Ep31: Metastatic Breast Cancer 2025 UPDATE
|
Oct 20, 2025 |
|
S14 Ep30: FDA Approval Insights: Subcutaneous Pembrolizumab for Solid Tumors: With J. Thaddeus Beck, MD, FACP
|
Oct 16, 2025 |
|
S14 Ep29: Passion and Innovation Formed the Foundation for a Leading Cancer Program: With Girindra Raval, MD; and Anand Jillella, MD
|
Oct 15, 2025 |
|
S14 Ep28: Oncology Experts Preview Key Studies Ahead of the 2025 ESMO Congress
|
Oct 13, 2025 |
|
S14 Ep27: FDA Approval Insights: Gemcitabine Intravesical System for NMIBC: With Joseph Jacob, MD, MCR
|
Oct 09, 2025 |
|
S14 Ep26: FDA Approval Insights: Sunvozertinib in EGFR-Mutated Metastatic NSCLC: With Lyudmila Bazhenova, MD
|
Oct 08, 2025 |
|
S14 Ep25: Sequencing, Efficacy, and Safety Data May Further Evolve the Role of Fruquintinib in CRC: With Kanwal P. S. Raghav, MBBS, MD
|
Oct 06, 2025 |
|
S14 Ep24: FDA Approval Insights: Maintenance Lurbinectedin Plus Atezolizumab for ES-SCLC: With Anne Chiang, MD, PhD; and Stephen Liu, MD
|
Oct 02, 2025 |
|
S14 Ep23: Early Biomarker Testing Optimizes Tepotinib Use in NSCLC With MET Exon 14 Skipping Mutations: With Stephen Liu, MD
|
Oct 01, 2025 |
|
S14 Ep22: Expanding JAK Inhibitor Use Offers Increased Treatment Options for Cytopenic Myelofibrosis: With Andrew Kuykendall, MD
|
Sep 29, 2025 |
|
S14 Ep21: Early CAR T-Cell Therapy Data Highlight Therapeutic Potential and Emerging Challenges in GI Cancers: With Kohei Shitara, MD
|
Sep 25, 2025 |
|
S14 Ep20: The Evolving Role of Noncovalent BTK Inhibition Informs CLL Treatment Selection: With Asad Dean, MD
|
Sep 24, 2025 |
|
S14 Ep19: Zidesamtinib Is Associated With CNS Activity and Low Rates of Neurologic AEs in Pretreated ROS1+ NSCLC: With Alexander Drilon, MD
|
Sep 18, 2025 |
|
S14 Ep18: Patient Characteristics and Disease Factors Guide the Use of Dostarlimab in Recurrent Endometrial Cancer: With Dana M. Chase, MD
|
Sep 17, 2025 |
|
S14 Ep17: Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC
|
Sep 16, 2025 |
|
S14 Ep16: Establishing the Rationale for ADC and ICI Combinations in TNBC
|
Sep 16, 2025 |
|
S14 Ep15: Cohort Analysis Shows Importance of Early-Onset CRC Awareness and Investigation: With Evelyn Y. Wong, MD
|
Sep 15, 2025 |
|
S14 Ep14: Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC
|
Sep 15, 2025 |
|
S14 Ep13: Dissecting Clinical Trial and Real-World Data for ADCs in TNBC
|
Sep 15, 2025 |
|
S14 Ep12: Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC
|
Sep 12, 2025 |
|
S14 Ep11: Breaking Down the Rationale for Targeting TROP2 in TNBC
|
Sep 12, 2025 |
|
S14 Ep10: Patient Characteristics and Care Team Collaboration Influence Treatment Decision-Making in CLL: With John N. Allan, MD; and Melissa Rubianes
|
Sep 11, 2025 |
|
S14 Ep9: Tepotinib Efficacy and Safety Profiles Underscore the Importance of Biomarker-Directed Decision-Making in NSCLC: With Balazs Halmos, MD, MS
|
Sep 09, 2025 |
|
S14 Ep8: Recent FDA Approvals and Ongoing Research Expand Treatment Options for Soft Tissue Sarcoma: With Samantha A. Armstrong, MD; and Karine Tawagi, MD
|
Sep 08, 2025 |
|
S14 Ep7: Clinical Trial and Real-World Data With NALIRIFOX Shape the Future of Pancreatic Cancer Care: With Tara E. Seery, MD; Paul E. Oberstein, MD; and Priyadarshini Pathak, MBBS
|
Sep 04, 2025 |
|
S14 Ep6: Advances in ctDNA Testing Guide Clinical Decision-Making in GI Cancer Management: With Scott Kopetz, MD, PhD, FACP
|
Sep 03, 2025 |
|
S14 Ep5: Safety and Quality-of-Life Considerations Shape ADT Use in Prostate Cancer: With Tanya B. Dorff, MD
|
Sep 02, 2025 |
|
S14 Ep4: FDA Approval Insights: Dordaviprone in H3K27M-Mutated Diffuse Midline Glioma: With Patrick Y. Wen, MD
|
Sep 01, 2025 |
|
S14 Ep3: FDA Approval Insights: Taletrectinib in ROS1+ Advanced/Metastatic NSCLC: With Joel Neal, MD, PhD; and Christian Rolfo, MD, PhD
|
Aug 28, 2025 |
|
S14 Ep2: FDA Approval Insights: Zongertinib in HER2-Mutated NSCLC: With Ticiana Leal, MD, and Misako Nagasaka, MD, PhD
|
Aug 27, 2025 |
|
S14 Ep1: Obe-Cel Data Are Poised to Refine and Expand the ALL Treatment Paradigm: With Aaron Logan, MD, PhD; and Bijal Shah, MD, MS
|
Aug 26, 2025 |
|
S13 Ep50: SUPRAME Trial Propels the Development of TCR-Based Therapy in Cutaneous Melanoma: With Jason Luke, MD
|
Aug 25, 2025 |
|
S13 Ep49: Distinguishing Pathway to Precision for c-Met and MET Alterations in NSCLC
|
Aug 22, 2025 |
|
S13 Ep48: Refining First-Line Immunotherapy Strategies in Hepatocellular Carcinoma: With Masatoshi Kudo, MD, PhD
|
Aug 21, 2025 |
|
S13 Ep47: Multidisciplinary Collaboration Gives Forward Momentum to HER2 IHC Testing in NSCLC: With Ronan J. Kelly, MD, MBA, FASCO; and Michelle Shiller, DO, AP/CP, MGP
|
Aug 19, 2025 |
|
S13 Ep46: FDA Approval Insights: Linvoseltamab in Relapsed/Refractory Multiple Myeloma: With Nisha Joseph, MD; and Hans Lee, MD
|
Aug 18, 2025 |
|
S13 Ep45: Exploring NCCN Guideline Updates and Advancing Immunotherapy Strategies in Nasopharyngeal Carcinoma: With Neal S. Akhave, MD
|
Aug 14, 2025 |
|
S13 Ep44: Frank’s Path to Advancing Hematology Through Innovation and Discovery: With Girindra Raval, MD; and David A. Frank, MD, PhD, FACP
|
Aug 13, 2025 |
|
S13 Ep43: Real-World Perspectives on mCRC and GI Neuroendocrine Neoplasms; With Rocío García-Carbonero, MD, PhD
|
Aug 12, 2025 |
|
S13 Ep42: Endometrial (Uterine) Cancer 2025 UPDATE
|
Aug 11, 2025 |
|
S13 Ep41: The European Approval of Mirdametinib Expands the Treatment Paradigm for NF1-Associated Plexiform Neurofibromas: With Ignacio Blanco, MD, PhD
|
Aug 07, 2025 |
|
S13 Ep40: The Role of Combination Checkpoint Blockade Is Evolving in MSI-H mCRC: With Elena Élez, MD, PhD
|
Aug 06, 2025 |
|
S13 Ep39: Efficacy of Immune Checkpoint Inhibition in Oncology May Translate to Neurologic Disorders: With Shailee S. Shah, MD
|
Aug 05, 2025 |
|
S13 Ep38: Guideline Updates and Trial Data Solidify the Role of HER2/MET IHC Testing in NSCLC: With Martin F. Dietrich, MD, PhD
|
Aug 04, 2025 |
|
S13 Ep37: Retrospective Data Highlight Improved Efficacy With Maintenance Therapy vs Treatment Breaks in mCRC: With Connie Lai, MD
|
Jul 31, 2025 |
|
S13 Ep36: CRISPR-Edited CISH Knockout TIL Therapy Paves Novel Treatment Paths in CRC: With Branden Moriarity, PhD; and Beau Webber, PhD
|
Jul 28, 2025 |
|
S13 Ep35: Telisotuzumab Vedotin Represents a New Treatment Development for c-Met–Overexpressing NSCLC: With Joshua K. Sabari, MD
|
Jul 24, 2025 |
|
S13 Ep34: Cortes’ Journey Helps Reshape Hematologic Cancer Care: With Girindra Raval, MD; and Jorge Cortes, MD
|
Jul 23, 2025 |
|
S13 Ep33: Isatuximab-Based Triplet Delivered via On-Body System Shows Promise in RRMM: With Xavier Leleu, MD, PhD; and Beth Faiman, PhD, MSN, APN-BC
|
Jul 21, 2025 |
|
S13 Ep32: European Approval of Zanidatamab Expands Treatment Options for HER2+ Biliary Tract Cancer: With Arndt Vogel, MD
|
Jul 17, 2025 |
|
S13 Ep31: IHC Testing Leads to Early Detection of TP53-Mutant AML and MDS: With Jonathan M. Gerber, MD; and Shyam A. Patel, MD, PhD
|
Jul 16, 2025 |
|
S13 Ep30: Biopsy-Guided Approach Enables Surgery Omission After pCR in HER2+ and Triple-Negative Breast Cancer: With Henry M. Kuerer, MD, PhD, FACS, CMQ
|
Jul 15, 2025 |
|
S13 Ep29: FDA Approval Insights: Oncomine DX Express Test Companion Diagnostic for Sunvozertinib in Non–Small Cell Lung Cancer: With Apar Kishor Ganti, MD; and Allison Cushman-Vokoun, MD, PhD, FCAP
|
Jul 14, 2025 |
|
S13 Ep28: Toripalimab Plus De-Intensified Chemo Represents the Potential Future of Nasopharyngeal Cancer Management: With Justine Bruce, MD
|
Jul 10, 2025 |
|
S13 Ep26: ASCO 2025 Plenary — MATTERHORN
|
Jul 07, 2025 |
|
S13 Ep25: FDA Approval Insights: Darolutamide for Metastatic Castration-Sensitive Prostate Cancer: With Alicia Morgans, MD, MPH; and Neal Shore, MD, FACS
|
Jul 03, 2025 |
|
S13 Ep24: Biomarker-Directed Therapies Improve Outlooks for the mCRC Treatment Arsenal: With Chandler Park, MD; and Midhun Malla, MD
|
Jul 02, 2025 |
|
S13 Ep23: IMA203 emerges as a Novel Investigational Agent in Cutaneous Melanoma: With Justin Moser, MD
|
Jun 30, 2025 |
|
S13 Ep22: BRAF-Mutant and HER2+ mCRC Management Strategies Are Becoming Increasingly Tailored: With Chandler Park, MD, and Midhun Malla, MD
|
Jun 26, 2025 |
|
S13 Ep21: T-DXd's Efficacy Stands Strong and Supports IHC Testing in HER2-Mutated NSCLC: With Misako Nagasaka, MD, PhD
|
Jun 25, 2025 |
|
S13 Ep20: ASCO 2025 Plenary: SERENA-6
|
Jun 24, 2025 |
|
S13 Ep19: Long-Term Data Underscore the Enduring Efficacy of PD-1 Inhibition in Nasopharyngeal Carcinoma: With Michael Dennis, MD
|
Jun 23, 2025 |
|
S13 Ep18: Conversations About BTK Inhibitors and CAR T-Cell Therapies Bridge Gaps in Leukemia and Lymphoma: With Alexey Danilov, MD, PhD
|
Jun 19, 2025 |
|
S13 Ep17: 42nd Annual Miami Breast Cancer Conference® Podcast: OncLive On Air CE, Powered by PER
|
Jun 18, 2025 |
|
S13 Ep16: Liquid Imatinib Formulation Expands Leukemia Treatment Options and Improves Treatment Adherence: With Kate Gasparini, PharmD, BCOP, BCPPS
|
Jun 17, 2025 |
|
S13 Ep15: The Expanding Role of AR Inhibition in mHSPC Management: With Alicia Morgans, MD, MPH
|
Jun 16, 2025 |
|
S13 Ep14: Revumenib Shows Promise Across Menin-Sensitive AML Subtypes and Could Shift Treatment Paradigms: With Naval Daver, MD
|
Jun 12, 2025 |
|
S13 Ep13: T-DXd Plus Pertuzumab Could Redefine First-Line HER2+ Breast Cancer Management: With Paolo Tarantino, MD
|
Jun 11, 2025 |
|
S13 Ep12: Telisotuzumab Vedotin Shakes Up Management of Pretreated, c-MET–Overexpressing NSCLC: With Jonathan W. Goldman, MD
|
Jun 10, 2025 |
|
S13 Ep11: Collaborative Structural Reforms Represent a Way Forward for Oncology Innovations: With Elizabeth Mittendorf, MD, PhD, MHCM
|
Jun 09, 2025 |
|
S13 Ep10: Updates and Innovations in Non-Opioid Pain Management Strategies for Breast Cancer Patients Post-Surgical Intervention
|
Jun 04, 2025 |
|
S13 Ep9: Multidisciplinary Collaboration and Mentorship Lay the Foundation for a New Chapter of ASCO Leadership: With Elizabeth Mittendorf, MD, PhD, MHCM
|
Jun 02, 2025 |
|
S13 Ep8: Oncology PER® Spectives: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma
|
Jun 02, 2025 |
|
S13 Ep7: Evolving Molecular Profiling and Liquid Biopsy Practices Guide First-Line CRC Therapy Decisions: With Chandler Park, MD; and Midhun Malla, MD
|
May 29, 2025 |
|
S13 Ep6: FDA Approval Insights: Perioperative Durvalumab Plus Chemo in MIBC: With Matthew Galsky, MD
|
May 28, 2025 |
|
S13 Ep5: Social Media Expands Access to Practical Public Health Education: With Chandler Park, MD; and Paul Hanona, MD
|
May 26, 2025 |
|
S13 Ep4: Eltrombopag Biosimilar Improves Accessibility for Immune Thrombocytopenia & Aplastic Anemia: With Kanwarpal S. Kahlon, MD
|
May 22, 2025 |
|
S13 Ep3: Updated Nilotinib Formulation Improves Treatment Adherence in Ph+ CML: With Michael J. Mauro, MD
|
May 19, 2025 |
|
S13 Ep2: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer
|
May 19, 2025 |
|
S13 Ep1: Cancer Vaccines Shake Up Disease Management and Prevention Strategies: With Shubham Pant, MD, MBBS; and Professor Timothy Elliott
|
May 15, 2025 |
|
S12 Ep50: Optimizing Today and Looking to Tomorrow in Metastatic CRPC - Homing in on EZH2
|
May 14, 2025 |
|
S12 Ep49: MEK Inhibitors Expand the NF1-Associated PN Treatment Paradigm: With Christopher L. Moertel, MD
|
May 12, 2025 |
|
S12 Ep48: Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation
|
May 12, 2025 |
|
S12 Ep47: Early-Phase RAS Inhibitor Research Sparks Interest in NSCLC: With Kathryn C. Arbour, MD
|
May 08, 2025 |
|
S12 Ep46: Managing Side Effects and Fertility for Premenopausal Patients with Advanced HR+ Breast Cancer
|
May 07, 2025 |
|
S12 Ep45: RP1 Plus Nivolumab Delivers Durable Responses in PD-1–Exposed Melanoma: With Anna C. Pavlick, BSN, MSc, DO, MBA
|
May 05, 2025 |
|
S12 Ep44: Real-World Data Support Nadofaragene Firadenovec Use in BCG-Unresponsive NMIBC: With Jacob Moyer, BS; and Mark D. Tyson, II, MD, MPH
|
May 01, 2025 |
|
S12 Ep43: Disease Features and Treatment Intolerance Inform Pirtobrutinib Use in Pretreated CLL: With Nicole Lamanna, MD
|
Apr 28, 2025 |
|
S12 Ep42: Radioligand Therapy Advances Represent the Future of mCRPC Treatment: With Daniel P. Petrylak, MD
|
Apr 24, 2025 |
|
S12 Ep41: Oncodetect MRD Detection Aids Treatment Decision-Making in CRC and Other Solid Tumors: With Eric Christenson, MD
|
Apr 23, 2025 |
|
S12 Ep40: Motivation and Consistency Are Key to Building a Successful Oncology Educational Platform: With Chandler Park, MD; and Paul Hanona, MD
|
Apr 21, 2025 |
|
S12 Ep39: Social Media Unlocks New Avenues for Expanding Access to Oncology Education: With Chandler Park, MD; and Paul Hanona, MD
|
Apr 16, 2025 |
|
S12 Ep38: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC
|
Apr 16, 2025 |
|
S12 Ep37: Bladder-Sparing Strategies and ctDNA-Guided Strategies Take Center Stage in MIBC: With Chandler Park, MD; and Vadim Koshkin, MD
|
Apr 14, 2025 |
|
S12 Ep36: Peer Support, Adaptability, and Self-Confidence Are Hallmarks of Successful Oncology Careers: With Liliana Bustamante, MD; and Jessica Stine, MD
|
Apr 10, 2025 |
|
S12 Ep35: Innovative Research Raises Questions About the Role of ADCs in Bladder Cancer: With Chandler Park, MD; and Vadim Koshkin, MD
|
Apr 09, 2025 |
|
S12 Ep34: AR Pathway Inhibition Refines Prostate Cancer Treatment Strategies: With Neal Shore, MD, FACS
|
Apr 07, 2025 |
|
S12 Ep33: Comprehensive First-Line Bladder Cancer Treatment Begins With Careful Patient Selection: With Chandler Park, MD
|
Apr 03, 2025 |
|
S12 Ep32: ADC-Based Combinations Gain Momentum in Bladder Cancer Management: With Chandler Park, MD; and Vadim Koshkin, MD
|
Apr 03, 2025 |
|
S12 Ep31: Oncology Experts Discuss the Long-Term Effects of the COVID-19 Pandemic: With Ramez N. Eskander, MD; Rachel N. Grisham, MD; Benjamin Herzberg, MD; Kelly McCann, MD, PhD; and Gregory Roloff, MD
|
Mar 31, 2025 |
|
S12 Ep30: Study Reveals Subgroups of Patients With RCC Who May Have Durable Responses to Immunotherapy: With David A. Braun, MD, PhD
|
Mar 27, 2025 |
|
S12 Ep29: Strong Mentorship Opportunities Support the Next Generations of Women in Lymphoma: With Chandler Park, MD; and Ann S. LaCasce, MD, MMSc
|
Mar 26, 2025 |
|
S12 Ep28: Ivonescimab Improves PFS vs Pembrolizumab in Advanced PD-L1+ NSCLC: With Xiuning Le, MD, PhD
|
Mar 24, 2025 |
|
S12 Ep28: Ponatinib Monotherapy Maintains MRD Negativity Following TKI/Chemotherapy Treatment in Ph+ ALL: With Ibrahim T. Aldoss, MD; and Elias Jabbour, MD
|
Mar 20, 2025 |
|
S12 Ep27: Venetoclax Plus Pegcrisantaspase Induces Remissions in R/R AML: With Ashkan Emadi, MD, PhD
|
Mar 17, 2025 |
|
S12 Ep26: FDA Approval Insights: Tislelizumab Plus Chemo in Unresectable Metastatic ESCC: With Nataliya Uboha, MD, PhD
|
Mar 13, 2025 |
|
S12 Ep25: Perioperative Durvalumab Improves Survival in MIBC: Navigating the NIAGARA Trial Findings With: Chandler Park, MD; and Petros Grivas, MD, PhD
|
Mar 12, 2025 |
|
S12 Ep24: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes
|
Mar 11, 2025 |
|
S12 Ep23: Inavolisib Expands the PIK3CA-Mutated Metastatic HR+ Breast Cancer Treatment Paradigm: With Virginia Kaklamani, MD, DSc
|
Mar 10, 2025 |
|
S12 Ep22: FDA Approval Insights: Vimseltinib for Symptomatic TGCT: With William D. Tap, MD
|
Mar 06, 2025 |
|
S12 Ep21: Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma
|
Mar 04, 2025 |
|
S12 Ep20: FDA Approval Insights: Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC: With Marwan Fakih, MD
|
Mar 03, 2025 |
|
S12 Ep19: FDA Approval Insights: T-DXd in HER2-Low/-Ultralow Metastatic Breast Cancer: With Aditya Bardia, MD, MPH, FASCO
|
Feb 27, 2025 |
|
S12 Ep18: Neoadjuvant MVAC/Pembrolizumab Generates Unprecedented pCR Rates in Non-Urothelial MIBC: With Chandler Park, MD; Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD
|
Feb 26, 2025 |
|
S12 Ep17: Triplet Chemo Trial Raises Importance of Accurately Defined Subgroups in Biliary Tract Cancer Research: With Rachna Shroff, MD, MS, FASCO
|
Feb 24, 2025 |
|
S12 Ep16: DA Approval Insights: Mirdametinib for NF1-Associated Plexiform Neurofibromas: With Christopher L. Moertel, MD
|
Feb 20, 2025 |
|
S12 Ep15: Inavolisib Has a Favorable Risk-Benefit Profile for PIK3CA-Mutant, HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP
|
Feb 17, 2025 |
|
S12 Ep14: FDA Approval Insights: Dato-DXd for HR+/HER2-Negative Metastatic Breast Cancer: With Aditya Bardia, MD, MPH, FASCO
|
Feb 13, 2025 |
|
S12 Ep13: Ponatinib-Based Regimens Strengthen the Ph+ ALL Treatment Paradigm: With Mark B. Geyer, MD, and Elias Jabbour, MD
|
Feb 10, 2025 |
|
S12 Ep12: Advances in RAS-Mutant PDAC Management Emphasize the Importance of Biomarker Testing: With Heinz-Josef Lenz, MD
|
Feb 06, 2025 |
|
S12 Ep10: Olverembatinib Research Signals a New Era of CP-CML Management: With Elias Jabbour, MD
|
Feb 03, 2025 |
|
S12 Ep9: How Second Primary Cancer Risk Factors Into CAR T-Cell Therapy Considerations: With Saurabh Dahiya, MD, FACP; and Shyam A. Patel, MD, PhD
|
Jan 30, 2025 |
|
S12 Ep8: How are Antibody-Drug Conjugates Shaping the NSCLC Treatment Paradigm? With David Gerber, MD
|
Jan 28, 2025 |
|
S12 Ep7: Blinatumomab-Based Regimens Enhance and Refine the B-ALL Treatment Paradigm: With Ryan Cassaday, MD
|
Jan 23, 2025 |
|
S12 Ep6: FDA Approval Insights: Subcutaneous Nivolumab for Advanced Solid Tumors: With Roxana S. Dronca, MD
|
Jan 20, 2025 |
|
S12 Ep5: MedNews Week Advances Global Oncology Education and Combats Misinformation: With Chandler Park, MD; and Yan Leyfman, MD
|
Jan 15, 2025 |
|
S12 Ep4: Oncogene Analysis Identifies Clinically Relevant Gene Copy Number Gain Thresholds in NSCLC: With Alec Watson, MD
|
Jan 13, 2025 |
|
S12 Ep3: Clinical Practice Insights Reveal the Complexity of Lymphoma Subtypes and Advances in First-Line Treatments: With Chandler Park, MD; and Joshua Brody, MD
|
Jan 08, 2025 |
|
S12 Ep2: Pembrolizumab Plus Preoperative Radiotherapy and Surgery Improves DFS in Soft-Tissue Sarcoma: With Yvonne Mowery, MD, PhD
|
Jan 07, 2025 |
|
S12 Ep1: FDA Approval Insights: Zenocutuzumab for NRG1+ Pancreatic Adenocarcinoma and NSCLC: With Alison Schram, MD
|
Jan 02, 2025 |
|
S11 Ep50: DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD
|
Jan 01, 2025 |
|
S11 Ep49: Explore the Evolving Role of BTK Inhibitors in CLL: With Alexey Danilov, MD, PhD; and Susan M. O'Brien, MD
|
Dec 31, 2024 |
|
S11 Ep48: FDA Approval Insights: Zanidatamab in Pretreated, HER2+ Biliary Tract Cancer
|
Dec 30, 2024 |
|
S11 Ep47: Exploring Luspatercept's Role in Anemia Management for Lower-Risk MDS: Insights From Dr. Jorge Cortes
|
Dec 24, 2024 |
|
S11 Ep46: The Evolving Role of ctDNA in Guiding Adjuvant Chemotherapy Decisions in CRC: Insights from Stacey A. Cohen, MD
|
Dec 24, 2024 |
|
S11 Ep45: Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD
|
Dec 23, 2024 |
|
S11 Ep44: Explore MRD Dynamics With Isa-VRd in Newly Diagnosed Multiple Myeloma: Insights From Philippe Moreau, MD
|
Dec 23, 2024 |
|
S11 Ep43: Zanubrutinib Leads the Way for Advancements in CLL Management: With Mazyar Shadman, MD, MPH
|
Dec 19, 2024 |
|
S11 Ep41: Unpacking Key Data From the 2024 ASH Annual Meeting: With Andre Goy, MD
|
Dec 18, 2024 |
|
S11 Ep42: Exploring Lasofoxifene Plus Abemaciclib in ESR1+ Breast Cancer: Insights from ELAINE-3 With Sagar D. Sardesai, MBBS
|
Dec 16, 2024 |
|
S11 Ep41: Explore Findings With Nivolumab Plus AVD in Advanced-Stage Classic Hodgkin Lymphoma: With Alex F. Herrera, MD
|
Dec 13, 2024 |
|
S11 Ep41: Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD
|
Dec 12, 2024 |
|
S11 Ep40: T-DXd Steadily Transforms the NSCLC Treatment Paradigm: With Misako Nagasaka, MD, PhD
|
Dec 10, 2024 |
|
S11 Ep40: How to Optimize Patient Selection for Multiple Myeloma Therapies: With Binod Dhakal, MD; and Muhamed Baljevic, MD
|
Dec 06, 2024 |
|
S11 Ep38: Pancreatic Cancer Research Surfaces Treatment Developments and Challenges: With John Strickler, MD
|
Dec 02, 2024 |
|
S11 Ep38: FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL
|
Nov 28, 2024 |
|
S11 Ep39: Explore the Latest Treatment Updates in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen V. Liu, MD
|
Nov 27, 2024 |
|
S11 Ep38: Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MD
|
Nov 25, 2024 |
|
S11 Ep37: Trastuzumab Deruxtecan Advances HER2+ Gynecologic Cancer Care: With Susana M. Campos, MD, MPH
|
Nov 21, 2024 |
|
S11 Ep36: HPV16-Targeted Immunotherapy Is Set to Personalize HNSCC Management: With Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB
|
Nov 18, 2024 |
|
S11 Ep35: FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma
|
Nov 14, 2024 |
|
S11 Ep34: Relacorilant Plus Nab-Paclitaxel Carves New Avenues of Platinum-Resistant Ovarian Cancer Care: With Premal Thaker, MD, MS
|
Nov 11, 2024 |
|
S11 Ep33: Explore Emerging Breast Cancer Treatment Trends With Kevin Kalinsky, MD, MS
|
Nov 07, 2024 |
|
S11 Ep32: Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD
|
Nov 06, 2024 |
|
S11 Ep31: How to Use Toripalimab Plus Chemotherapy in Nasophryngeal Carcinoma: With Tarek Mekhail, MD, MSC, FRCSI, FRCSEd
|
Nov 04, 2024 |
|
S11 Ep30: SUNLIGHT QOL Data Show Positive Outcomes With T rifluridine-Tipiracil Plus Bevacizumab in CRC : With Joleen Hubbard, MD
|
Oct 31, 2024 |
|
S11 Ep29: Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
|
Oct 30, 2024 |
|
S11 Ep28: Liquid Biopsy Ushers in a New Era of NSCLC Biomarker Testing: With David R. Gandara, MD
|
Oct 28, 2024 |
|
S11 Ep27: Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD
|
Oct 24, 2024 |
|
S11 Ep26: Phase 1 Trials Provide Oncology Fellows With Valuable Clinical Research Experience: With Samuel A. Kareff, MD, MPH
|
Oct 21, 2024 |
|
S11 Ep25: FDA Approval Insights: Denileukin Diftitox in Relapsed/Refractory CTCL
|
Oct 17, 2024 |
|
S11 Ep24: How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
|
Oct 16, 2024 |
|
S11 Ep23: Navigating Myelofibrosis: Updates for Community Hematologist Oncologists
|
Oct 14, 2024 |
|
S11 Ep22: FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma
|
Oct 10, 2024 |
|
S11 Ep21: Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD
|
Oct 07, 2024 |
|
S11 Ep20: FDA Approval Insights: Perioperative Durvalumab for Resectable NSCLC
|
Oct 03, 2024 |
|
S11 Ep19: Immunotherapy Advances Expand the SCLC Treatment Paradigm: With Chandler Park, MD, and Tejas Patil, MD
|
Oct 02, 2024 |
|
S11 Ep18: Board Review Resources 2024
|
Sep 30, 2024 |
|
S11 Ep17: How Luspatercept Could Shake Up MDS Management—With Rory Shallis, MD
|
Sep 26, 2024 |
|
S11 Ep16: FDA Approval Insights: Afami-Cel for Pretreated, Unresectable or Metastatic Synovial Sarcoma
|
Sep 23, 2024 |
|
S11 Ep15: Thomas and Lukas Highlight Updates in Brain Cancer from the 2024 ASCO Annual Meeting
|
Sep 19, 2024 |
|
S11 Ep14: Park and Patil Explore Advances in EGFR + NSCLC From ASCO 2024
|
Sep 18, 2024 |
|
S11 Ep13: FDA Approval Insights: Epcoritamab in Relapsed/Refractory Follicular Lymphoma
|
Sep 16, 2024 |
|
S11 Ep12: Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress
|
Sep 11, 2024 |
|
S11 Ep11: Heme & Onc Fellow Board Review Tips 2024
|
Sep 09, 2024 |
|
S11 Ep10: Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions
|
Sep 05, 2024 |
|
S11 Ep9: Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer
|
Sep 04, 2024 |
|
S11 Ep8: Salgia Summarizes the Benefits of Tepotinib in MET Exon 14–Mutated NSCLC
|
Sep 02, 2024 |
|
S11 Ep7: Chiang Contextualizes the Optimal Use of Lurbinectedin in SCLC Management
|
Aug 29, 2024 |
|
S11 Ep6: FDA Approval Insights: Dostarlimab Plus Chemotherapy in Advanced/Recurrent Endometrial Cancer
|
Aug 26, 2024 |
|
S11 Ep5: Jhaveri on the INAVO120 Trial of Inavolisib/Palbociclib/Fulvestrant in PIK3CA -Mutant, HR+ Breast Cancer
|
Aug 22, 2024 |
|
S11 Ep4: Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC
|
Aug 21, 2024 |
|
S11 Ep3: Garcia-Manero on MDS Treatment Updates With Luspatercept and Beyond
|
Aug 19, 2024 |
|
S11 Ep3: FDA Approval Insights: Durvalumab/Chemotherapy in dMMR Advanced Endometrial Cancer
|
Aug 15, 2024 |
|
S11 Ep2: ASCO 2024 Plenary: NADINA Trial Neoadjuvant Ipi/Nivo vs Adjuvant Nivo for Resectable Stage III Melanoma
|
Aug 12, 2024 |
|
S11 Ep1: Rotow Reviews Key Updates on the Management of CNS Metastases in NSCLC
|
Aug 08, 2024 |
|
S10 Ep50: Park and Grivas Expand on Treatment Updates in Bladder Cancer
|
Aug 07, 2024 |
|
S10 Ep49: Halmos on the AE Profiles of Dato-DXd and Other ADCs in NSCLC
|
Aug 05, 2024 |
|
S10 Ep48: Lisberg Lends Insight About the TROPION-Lung01 Trial of Dato-DXd in NSCLC
|
Aug 01, 2024 |
|
S10 Ep47: Pegram Details the Use of Oral SERDs in ESR1+ Metastatic Breast Cancer
|
Jul 29, 2024 |
|
S10 Ep47: Miller Discusses the Use of Selinexor in TP53 Wild-Type Advanced Endometrial Cancer
|
Jul 25, 2024 |
|
S10 Ep46: Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer
|
Jul 24, 2024 |
|
S10 Ep45: Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComa
|
Jul 18, 2024 |
|
S10 Ep44: Curigliano on the DESTINY-Breast06 Trial in HER2-Low and -Ultralow Metastatic Breast Cancer
|
Jul 15, 2024 |
|
S10 Ep43: Orlowski on Isa-VRd in Transplant-Ineligible Multiple Myeloma
|
Jul 11, 2024 |
|
S10 Ep42: Park and Sonpavde on Nivolumab Plus Gemcitabine/Cisplatin in Cisplatin-Eligible Urothelial Cancer
|
Jul 10, 2024 |
|
S10 Ep41: ASCO 2024 Plenary: ADRIATIC Trial in Limited-Stage Small Cell Lung Cancer
|
Jul 08, 2024 |
|
S10 Ep40: FDA Approval Insights: Imetelstat in Lower-Risk MDS and Transfusion-Dependent Anemia
|
Jul 01, 2024 |
|
S10 Ep39: Dietrich and Shiller Dive Into the Importance of Oncology Reflex Testing
|
Jun 27, 2024 |
|
S10 Ep38: Agulnik Highlights Key Updates in GIST Research and Management
|
Jun 24, 2024 |
|
S10 Ep37: Reckamp Discusses the Integration of Pragmatic Elements Into Oncology Clinical Trial Designs
|
Jun 20, 2024 |
|
S10 Ep36: Rosenberg Reviews the Evolving Role of Toripalimab in Nasopharyngeal Carcinoma
|
Jun 17, 2024 |
|
S10 Ep35: ASCO 2024 Plenary: LAURA Trial in Unresectable Stage III EGFRm NSCLC
|
Jun 10, 2024 |
|
S10 Ep35: Paik Provides Insights Into Tepotinib Treatment in NSCLC Harboring MET Exon 14 Skipping Alterations
|
Jun 06, 2024 |
|
S10 Ep34: Lenz Discusses the Prognostic and Predictive Value of HER2 Gene Expression in KRAS Wild-Type mCRC
|
Jun 03, 2024 |
|
S10 Ep33: Levy Lends Insights Into the Current and Future Use of ADCs in NSCLC
|
May 30, 2024 |
|
S10 Ep33: Park and Sonpavde on Considerations for Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer
|
May 30, 2024 |
|
S10 Ep32: Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
|
May 23, 2024 |
|
S10 Ep31: Ganjoo Discusses Treatment Plans, Patient Conversations, and the Role of Nab-Sirolimus in Malignant PEComa
|
May 20, 2024 |
|
S10 Ep30: Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer
|
May 13, 2024 |
|
S10 Ep30: Kummar on the Investigation of Rezatapopt in TP53 Y220C–Mutated Advanced Solid Tumors
|
May 09, 2024 |
|
S10 Ep30: Goy Gives Insights Into the Future Management of Lymphoma and Multiple Myeloma
|
May 06, 2024 |
|
S10 Ep29: Merkow and Connell Highlight Considerations for HAI Pump Use in CRC
|
May 02, 2024 |
|
S10 Ep28: Bou Farhat and Nassar on the Use of NGS Mutation Signature vs IHC for Identifying dMMR Tumors
|
Apr 29, 2024 |
|
S10 Ep27: FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy
|
Apr 22, 2024 |
|
S10 Ep26: Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma
|
Apr 18, 2024 |
|
S10 Ep25: Breast Cancer Experts Share Obstacles and Successes as Women in Oncology
|
Apr 11, 2024 |
|
S1 Ep18: FDA Approval Insights: Ponatinib in Ph+ ALL
|
Apr 08, 2024 |
|
S10 Ep24: Schmid Summarizes Updates in HER2-Positive Breast Cancer Management
|
Apr 01, 2024 |
|
S10 Ep23: Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa
|
Mar 28, 2024 |
|
S10 Ep22: CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib
|
Mar 25, 2024 |
|
S10 Ep21: Bagley Summarizes the ACTION trial of ONC201 in H3 K27M–Mutant Diffuse Midline Gliomas
|
Mar 21, 2024 |
|
S10 Ep20: Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies
|
Mar 18, 2024 |
|
S10 Ep19: FDA Approval Insights: NALIRIFOX in Metastatic Pancreatic Cancer
|
Mar 11, 2024 |
|
S10 Ep18: Dr Kyriakopoulos on the Investigation of Masofaniten Plus Enzalutamide in mCRPC
|
Mar 07, 2024 |
|
S10 Ep17: Kang Highlights Considerations for the Integration of Toripalimab into Nasopharyngeal Carcinoma Clinical Practice
|
Feb 29, 2024 |
|
S10 Ep16: Mims Expands on the Evaluation of Emavusertib in the TakeAim Leukemia Trial of AML and MDS
|
Feb 26, 2024 |
|
S10 Ep15: Tripathy Talks Through the Enduring Impact of the Miami Breast Cancer Conference
|
Feb 22, 2024 |
|
S10 Ep14: Kitco and Patel Emphasize the Importance of GVHD Research and Awareness
|
Feb 19, 2024 |
|
S10 Ep13: FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced/Metastatic Urothelial Carcinoma
|
Feb 12, 2024 |
|
S10 Ep12: Community Oncologists on the Importance of Self-Reliance and Collegial Trust as Women in Medicine
|
Feb 08, 2024 |
|
S10 Ep11: Lunning and Brander Emphasize the Importance of Early CLL Diagnosis and Treatment
|
Feb 05, 2024 |
|
S10 Ep10: Expert and Patient Perspectives on AE Management With FGFR Inhibitors in Cholangiocarcinoma
|
Jan 29, 2024 |
|
S10 Ep9: FDA Approval Insights: Pirtobrutunib in Previously Treated CLL/SLL
|
Jan 25, 2024 |
|
S10 Ep8: Lunning and Maddocks Talk Through Frontline MCL Management
|
Jan 22, 2024 |
|
S10 Ep7: FDA Approval Insights: Nirogacestat in Progressing Desmoid Tumors Requiring Systemic Treatment
|
Jan 15, 2024 |
|
S10 Ep6: Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers
|
Jan 11, 2024 |
|
S10 Ep5: Donington and Stiles Summarize NSCLC Resectability Parameters and Multidisciplinary Management
|
Jan 08, 2024 |
|
S10 Ep4: FDA Approval Insights: Capivasertib Plus Fulvestrant in Advanced HR+/HER2- Breast Cancer With PIK3CA, AKT1, or PTEN Alterations
|
Jan 04, 2024 |
|
S10 Ep3: Santos Summarizes Key Updates From EMPOWER-Lung 1 and EMPOWER-Lung 3 With Cemiplimab in NSCLC
|
Jan 01, 2024 |
|
S10 Ep2: Jabbour Reports Top Takeaways From ASH 2023 of Olverembatinib in CML and ALL
|
Dec 28, 2023 |
|
S10 Ep1: Eskander Emphasizes the Importance of Inclusivity and Accessibility in Oncology Clinical Trials
|
Dec 25, 2023 |
|
S9 Ep50: Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL
|
Dec 21, 2023 |
|
S9 Ep49: Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors
|
Dec 18, 2023 |
|
S9 Ep48: Donington and Stiles Describe the Surgical Implications of Lung Cancer Treatment Evolutions
|
Dec 11, 2023 |
|
S9 Ep47: Abdou Spotlights Factors Influencing ADC Treatment Selection in Breast Cancer
|
Dec 07, 2023 |
|
S9 Ep46: FDA Approval Insights: Toripalimab in Recurrent/Metastatic Nasopharyngeal Carcinoma
|
Dec 04, 2023 |
|
S9 Ep45: Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
|
Nov 30, 2023 |
|
S9 Ep44: Dumbrava Details Ongoing Research With PC14586 in p53 Y220C–Mutated Advanced Solid Tumors
|
Nov 23, 2023 |
|
S9 Ep43: FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome
|
Nov 20, 2023 |
|
S9 Ep42: Halmos Highlights Evaluation of the EGFR Inhibitor BDTX-1535 in NSCLC
|
Nov 16, 2023 |
|
S9 Ep41: Feigin Discusses the Association Between Benzodiazepines and Pancreatic Cancer Outcomes
|
Nov 13, 2023 |
|
S9 Ep40: Khouri Highlights the Ongoing AFFIRM-AL Trial in AL Amyloidosis
|
Nov 09, 2023 |
|
S9 Ep39: FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma
|
Nov 06, 2023 |
|
S9 Ep38: Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma
|
Oct 30, 2023 |
|
S9 Ep37: Naumann Discusses Notable Research Efforts in Endometrial Cancer
|
Oct 26, 2023 |
|
S9 Ep36: Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection
|
Oct 23, 2023 |
|
S9 Ep35: Hasanuma Highlights the Benefits of Building Authentic Connections Through Mentorship
|
Oct 19, 2023 |
|
S9 Ep34: FDA Approval Insights: Momelotinib in Myelofibrosis With Anemia
|
Oct 16, 2023 |
|
S9 Ep33: Gutierrez and Leslie Discuss Recent Efforts and Future Advances in CAR T-Cell Therapy
|
Oct 12, 2023 |
|
S9 Ep32: Expert Insights on the United States Chemotherapy Shortage
|
Oct 09, 2023 |
|
S9 Ep31: FDA Approval Insights: First-Line Luspatercept for Anemia in Lower-Risk MDS
|
Oct 05, 2023 |
|
S9 Ep30: Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma
|
Oct 02, 2023 |
|
S9 Ep29: Garcia-Manero and Zeidan Highlight Key Implications of the COMMANDS Trial in Lower-Risk MDS
|
Sep 28, 2023 |
|
S9 Ep28: FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma
|
Sep 21, 2023 |
|
S9 Ep27: Jones and Somaiah Review the Rationale and Design of the Peak Trial in GIST
|
Sep 18, 2023 |
|
S9 Ep26: Chuong Discusses the Importance of MRI-Guided Radiotherapy in Cancer
|
Sep 14, 2023 |
|
S9 Ep25: Fonkoua Sheds Light on Liver Cancer Clinical Trial Disparities
|
Sep 11, 2023 |
|
S9 Ep24: FDA Approval Insights: Talquetamab in Relapsed/Refractory Multiple Myeloma
|
Sep 07, 2023 |
|
S9 Ep23: Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
|
Sep 04, 2023 |
|
S9 Ep22: Kelley Discusses Efficacy and Safety Considerations With the STRIDE Regimen in HCC
|
Aug 31, 2023 |
|
S9 Ep21: FDA Approval Insights: Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced Endometrial Cancer
|
Aug 28, 2023 |
|
S9 Ep20: FDA Approval Insights: Quizartinib in Newly Diagnosed, FLT3-ITD+ AML
|
Aug 21, 2023 |
|
S9 Ep19: Trent Breaks Down Mutation Testing and ctDNA Monitoring in GIST
|
Aug 17, 2023 |
|
S9 Ep18: Bhatnagar Spotlights Ongoing Uproleselan Investigations in AML
|
Aug 14, 2023 |
|
S9 Ep17: Sanai Spotlights Meningioma Symptoms, Treatment Options, and Research Needs
|
Aug 10, 2023 |
|
S9 Ep16: Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers
|
Aug 07, 2023 |
|
S9 Ep15: FDA Approval Insights: Glofitamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
|
Aug 03, 2023 |
|
S9 Ep14: Trent Talks Through Potential Clinical Applications and Future Directions for MRD in GIST
|
Jul 31, 2023 |
|
S9 Ep13: Lunning and Kamdar Debate the Role of Pola-R-CHP in Treatment-Naïve DLBCL
|
Jul 24, 2023 |
|
S9 Ep12: Khan and Kwendakwema Discuss Financial Toxicity in Patients With Cancer
|
Jul 20, 2023 |
|
S9 Ep11: FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC
|
Jul 17, 2023 |
|
S9 Ep10: Lunning and Abramson Spotlight Developments and Challenges in LBCL Research and Management
|
Jul 13, 2023 |
|
S9 Ep9: FDA Approval Insights: Avapritinib in Indolent Systemic Mastocytosis
|
Jul 10, 2023 |
|
S9 Ep8: King Describes Unmet Needs and the Role of Surgical Resection in Residual Non-RP Testicular Cancer
|
Jul 06, 2023 |
|
S9 Ep7: Kremyanskaya Highlights the Benefits of BET Inhibitors in Myelofibrosis
|
Jul 03, 2023 |
|
S9 Ep6: Short Shares Post-Conference Perspectives in Acute Lymphoblastic Leukemia From ASCO and EHA 2023
|
Jun 29, 2023 |
|
S9 Ep5: Manana Discusses Systemic Racism in Oncology and Future Steps for Equitable Cancer Care
|
Jun 22, 2023 |
|
S9 Ep4: Reuss Reviews the Development of LP-300 in Advanced NSCLC
|
Jun 19, 2023 |
|
S9 Ep3: FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC
|
Jun 15, 2023 |
|
S9 Ep2: FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL
|
Jun 12, 2023 |
|
S9 Ep1: Holowatyj Highlights Challenges and Opportunities in Appendix Cancer Research
|
Jun 08, 2023 |
|
S8 Ep50: Raskin Reflects on the Career-Long Role of Fellowship and Education in Orthopaedic Oncology
|
Jun 05, 2023 |
|
S8 Ep49: Andreeff Sheds Light on the Evaluation of the E-selectin Antagonist Uproleselan in AML
|
May 29, 2023 |
|
S8 Ep48: Gottschalk and Krenciute Discuss the Development of CAR T-cell Therapy in Pediatric Solid Tumors
|
May 25, 2023 |
|
S8 Ep47: Mutale Discusses Disparities in Cancer Clinical Trial Eligibility, Access and Enrollment
|
May 22, 2023 |
|
S8 Ep46: Oncology Professionals Explain the Nuances of Career-Building Mentorship and Self-Advocacy
|
May 18, 2023 |
|
S8 Ep45: FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant
|
May 15, 2023 |
|
S8 Ep44: Haffner Highlights Treatment and Research Considerations for Basal Cell Carcinoma of the Prostate
|
May 11, 2023 |
|
S8 Ep43: Ehrhardt Explains the Effects of Modifiable Health Conditions on Late Mortality for Childhood Cancer Survivors
|
May 08, 2023 |
|
S8 Ep41: Stand Up to Cancer Grant Recipients Discuss Initiative to Expand Access to Early-Phase Clinical Trials
|
May 01, 2023 |
|
S8 Ep40: Kim Discusses the Development of LP-300 Plus Chemotherapy in Advanced Lung Cancer
|
Apr 27, 2023 |
|
S8 Ep39: FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma
|
Apr 24, 2023 |
|
S8 Ep38: Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer
|
Apr 20, 2023 |
|
S8 Ep37: Desai Discusses the Significance of a Supportive, Foundational Fellowship Experience
|
Apr 17, 2023 |
|
S8 Ep36: FDA Approval Insights: Dostarlimab in dMMR Advanced Endometrial Cancer
|
Apr 13, 2023 |
|
S8 Ep35: Gynecologic Cancer Experts Review 2023 SGO Research and Treatment Updates
|
Apr 10, 2023 |
|
S8 Ep34: Mercado and Kovacs Emphasize the Importance of Multidisciplinary Lung Cancer Screening and Management
|
Apr 06, 2023 |
|
S8 Ep33: Kishan Discusses GI Toxicity Reduction With MRI-Guided SBRT in Prostate Cancer
|
Apr 03, 2023 |
|
S8 Ep32: FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer
|
Mar 30, 2023 |
|
S8 Ep31: Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration
|
Mar 27, 2023 |
|
S8 Ep29: FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast Cancer
|
Mar 20, 2023 |
|
S8 Ep28: Raez Reports Benefits of Liquid Biopsy in Newly Diagnosed NSCLC
|
Mar 16, 2023 |
|
S8 Ep27: Milner, Dalal, and Ligon Discuss Stem Cell Transplant Methods, Results, and Risk Factors in Pediatric Patients
|
Mar 13, 2023 |
|
S8 Ep26: FDA Approval Insights: Adjuvant Pembrolizumab in Stage IB, II, or IIIA NSCLC
|
Mar 09, 2023 |
|
S8 Ep25: CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice
|
Mar 06, 2023 |
|
S8 Ep24: Jakubowiak Highlights PFS Benefit Seen With KRd Maintenance in Newly Diagnosed Multiple Myeloma
|
Mar 02, 2023 |
|
S8 Ep23: FDA Approval Insights: Pirtobrutinib in MCL
|
Feb 27, 2023 |
|
S8 Ep22: Mascarenhas Summarizes Therapeutic Standards and Advances in Myelofibrosis Management
|
Feb 23, 2023 |
|
S8 Ep21: FDA Approval Insights: Zanubrutinib in CLL and SLL
|
Feb 16, 2023 |
|
S8 Ep20: Small and Reagan Review Tumor Lysis Syndrome Risk Factors and Management Strategies
|
Feb 13, 2023 |
|
S8 Ep19: D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor
|
Feb 09, 2023 |
|
S8 Ep19: FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC
|
Feb 06, 2023 |
|
S8 Ep18: Rosenthal Discusses the Need for Standardized Care in AYA Hodgkin Lymphoma
|
Feb 02, 2023 |
|
S8 Ep17: Nair Notes the Benefits of Yoga as a Complementary Therapy in Nonmetastatic Breast Cancer
|
Jan 30, 2023 |
|
S8 Ep17: FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC
|
Jan 26, 2023 |
|
S8 Ep16: Goetz and Choong Describe the Need for Adjuvant Endocrine Therapy in ER-positive Breast Cancer
|
Jan 23, 2023 |
|
S8 Ep15: Dy Discusses CEACAM5-Directed and Other Second-Line Treatment Strategies in NSCLC
|
Jan 19, 2023 |
|
S8 Ep14: Giacchetti Discusses the Convergence of Chronobiology and Oncologic Care in Breast Cancer
|
Jan 16, 2023 |
|
S8 Ep14: Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL
|
Jan 12, 2023 |
|
S8 Ep12: Breast Cancer Experts Review HR+ Treatment Updates From SABCS 2022
|
Jan 05, 2023 |
|
S8 Ep11: Oppong Emphasizes How Patient Education Can Lower Breast Cancer Surgery Refusal Rates
|
Jan 02, 2023 |
|
S8 Ep10: Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors
|
Dec 29, 2022 |
|
S8 Ep9: Rugo Summarizes Developments With Ribociclib and ADCs in HR-Positive Breast Cancer
|
Dec 26, 2022 |
|
S8 Ep8: Expert and Patient Perspectives on Comprehensive Multiple Myeloma Treatment
|
Dec 22, 2022 |
|
S8 Ep7: Blum Highlights Implications of CA-125 Levels in Renal Medullary Carcinoma
|
Dec 19, 2022 |
|
S8 Ep6: FDA Approval Insights: Tremelimumab Plus Durvalumab and Chemotherapy in NSCLC
|
Dec 15, 2022 |
|
S8 Ep5: Acuna Discusses US Liver Cancer Incidence in Individuals of Mexican Descent
|
Dec 12, 2022 |
|
S8 Ep4: Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL
|
Dec 08, 2022 |
|
S8 Ep3: FDA Approval Insights: Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
|
Dec 05, 2022 |
|
S8 Ep2: Leone Lays Out Research Needs and Treatment Approaches in Male Breast Cancer
|
Dec 01, 2022 |
|
S8 Ep1: Florez Discusses Crucial Aspects of Cancer Care Equity and Survivorship
|
Nov 28, 2022 |
|
S7 Ep50: FDA Approval Insights: Durvalumab Plus Tremelimumab in HCC
|
Nov 24, 2022 |
|
S7 Ep49: Crane Helps Gynecologic Fellows Deliver Care in a Complicated Time
|
Nov 21, 2022 |
|
S7 Ep48: Oppong Sheds Light on Racial Disparities in Breast Cancer Diagnosis and Mortality
|
Nov 17, 2022 |
|
S7 Ep47: FDA Approval Insights: Teclistamab in Relapsed/Refractory Multiple Myeloma
|
Nov 14, 2022 |
|
S7 Ep46: Lunning Lends Insight on Pivotal Data From Pan Pacific Lymphoma 2022
|
Nov 10, 2022 |
|
S7 Ep45: Sauter and Hill Talk Through CAR T Cell Sequencing and Access in Lymphomas
|
Nov 07, 2022 |
|
S7 Ep44: FDA Approval Insights: Futibatinib in FGFR2-Positive Cholangiocarcinoma
|
Nov 03, 2022 |
|
S7 Ep43: Thymic Cancer Experts Discuss the Latest Data, Need for More Research Funding
|
Oct 31, 2022 |
|
S7 Ep42: Mikhael and Cole Share Insights on Culturally Relevant Myeloma Care
|
Oct 27, 2022 |
|
S7 Ep41: FDA Approval Insights: Sodium Thiosulfate in Cisplatin-Treated Pediatric Solid Tumors
|
Oct 24, 2022 |
|
S7 Ep40: Leukemia Experts Discuss Early Career Growth, Mentorship, and Gender Bias in Academia
|
Oct 20, 2022 |
|
S7 Ep39: Community Perspectives on Integrating and Interpreting Molecular Testing Results in NSCLC
|
Oct 17, 2022 |
|
S7 Ep38: FDA Approval Insights: Selpercatinib in RET Fusion–Positive Solid Tumors
|
Oct 13, 2022 |
|
S7 Ep37: Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
|
Oct 10, 2022 |